InfuSystem (INFU) Reports Higher Fourth Quarter 2012 Revenues

InfuSystem Holdings, Inc. (NYSE MKT: INFU) (“InfuSystem” or the “Company”), a leading national provider of infusion pumps and related services for the healthcare industry in the United States, today reported its second consecutive quarter of profitability in the fourth quarter ending December 31, 2012.

Net income in the fourth quarter was $0.2 million, equal to $0.01 per diluted share, compared to a $0.8 million net loss, or $0.04 loss per diluted share, in the prior year period. For the full year ended December 31, 2012, the Company’s net loss was $1.5 million, or $0.07 per diluted share, versus a net loss of $45.4 million, or $2.16 per diluted share, in 2011. The prior- year period included a $67.6 million asset impairment charge.

Gross profit for the three months ending December 31, 2012, was $12.0 million, up 48% from $8.1 million in the fourth quarter of 2011. Gross profit for the full year 2012 was $42.9 million, an increase of 21% compared to $35.4 million in 2011.

Revenues in the fourth quarter were $16.2 million, up 16% from $14.0 million in the fourth quarter of 2011. Total revenues for the year ended December 31, 2012, were $58.8 million, an 8% improvement from $54.6 million in 2011. The increase in revenues is primarily related to the addition of larger customers, increased penetration into existing customer accounts, and the resolution of the oncology drug shortage from 2011. Also, during the fourth quarter of 2012, a major group of third party payors revised their claim processing guidelines that affected all durable medical equipment providers, which pushed some claims to be billed at higher out-of-network rates directly to patients.

SG&A increased to $10.4 million from $8.8 million, in addition to other expenses of $1.2 million compared with $0.5 million of other income a year ago. Adjusted EBITDA for the latest quarter was $3.8 million, up from the $1.5 million for the prior-year period, as adjusted on a comparable basis.

“We are very pleased with our improved fourth quarter performance and fiscal year-over-year growth for the Company,” said Dilip Singh, Interim Chief Executive Officer. “The Company has accumulated annualized cost-savings of approximately $1.6 million since the current management team took control in April of 2012. That, combined with our securing a new debt facility during the fourth quarter, has helped restore the Company’s liquidity and create a far stronger balance sheet. Equally important, we have generated sufficient momentum to increase the number of third-party payor relationships and expand our provider footprint while delivering best in class service and patient satisfaction. Our efforts are now clearly focused on sustaining long-term growth,” Singh added.

Operating Results

Gross profit for the year ended December 31, 2012 was $42.9 million, an increase of 21% compared to $35.4 million in the prior year. It represented 73% of revenues in the current year compared to 65% in the prior year. The increase in the gross margin as a percentage of revenue in 2012 was primarily related to the increase in rental revenue, specifically third party billings, which generally have a higher gross profit margin.

Selling and marketing expenses were $9.9 million compared to $9.4 million for the year ended December 31, 2011. The increase in selling and marketing expenses is primarily related to expenses incurred by the increase in associated revenues as well as increased retention and travel costs. Compared to the prior year, these expenses remained consistent at 17% of revenues.

During the year ended December 31, 2012, general and administrative expenses were $23.1 million, compared to $18.0 million for the year ended December 31, 2011. General and administrative expenses have increased from 33% to 39% of revenues for the year ended December 31, 2012 compared to the same period in the prior year. The increase was primarily due to an increase in professional service costs related to the Concerned Stockholder Group. Additional legal, accounting and outside service fees of $2.2 million were incurred during the year relating to this matter and the related early extinguishment of debt; severance payments for the former CEO amounted to $1.0 million; $0.6 million was recorded for retention payments to key employees during this ongoing matter; and we incurred $0.6 million associated with our decision to evaluate potential strategic alternatives.

Additional increases were mainly attributed to an increase in finance and accounting staff and several other general and administrative accounts. These costs were partially offset by the reversal of previously recognized stock compensation expense of $1.4 million.

Adjusted EBITDA was $13.1 million for the latest fiscal year. This compares to 2011’s adjusted EBITDA, adjusted on a comparable basis, of $10.3 million. The Company utilizes Adjusted EBITDA as a means to measure its operating performance. A reconciliation from Adjusted EBITDA, a non-GAAP measure, to net income can be found in the appendix.

Financial Condition

Net cash provided by operations for fiscal 2012 was $5.5 million, down from the $6.7 million for the prior year. This decrease is mainly attributed to higher accounts receivable levels due to the higher revenue in the fourth quarter of 2012. As of December 31, 2012, we had cash and cash equivalents of $2.3 million and $4.7 million of availability on the revolving line-of-credit compared to $0.8 million and $4.9 million of availability on the revolving line-of-credit at December 31, 2011. This increase is due to the new credit facility and better cash management during the year.

Conference Call

The Company will conduct a conference call for investors on Thursday, March 28, 2013 at 9:00 a.m. Eastern Time to discuss fourth quarter performance and results. Dilip Singh, Interim Chief Executive Officer, and Jonathan P. Foster, Chief Financial Officer, will discuss the Company’s financial performance and answer questions from the financial community. To participate in this call, please dial in toll-free (888) 895-5479 and use the confirmation number 34394082.

About InfuSystem Holdings, Inc.

InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services to hospitals, oncology practices and other alternate site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, and Ontario, Canada. The Company’s stock is traded on the NYSE MKT under the symbol INFU.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. These risks and uncertainties include general economic conditions, as well as other risks, detailed from time to time in the Company’s publicly filed documents.

Additional information about InfuSystem Holdings, Inc. is available at www.infusystem.com.

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS
						December 31,						December 31,
(in thousands, except share data)						2012						2011
ASSETS
Current Assets:
Cash and cash equivalents						$	2,326					$	799
Accounts receivable, less allowance for doubtful accounts of $3,136 and
$1,773 at December 31, 2012 and December 31, 2011, respectively							8,511						7,350
Accounts receivable – related party							–						98
Inventory							1,339						1,309
Other current assets							684						934
Deferred income taxes							1,971						682
Total Current Assets							14,831						11,172
Medical equipment held for sale or rental							2,626						2,013
Medical equipment in rental service, net of accumulated depreciation							13,071						14,732
Property & equipment, net of accumulated depreciation							867						927
Deferred debt issuance costs, net							2,362						421
Intangible assets, net							25,541						28,221
Deferred income taxes							17,806						18,187
Other assets							419						590
Total Assets						$	77,523					$	76,263
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable						$	2,135					$	4,004
Accounts payable – related party							9						59
Derivative liabilities							–						258
Current portion of long-term debt							3,953						6,576
Other current liabilities							4,098						2,235
Total Current Liabilities							10,195						13,132
Long-term debt, net of current portion							27,315						22,551
Other liabilities							–						415
Total Liabilities						$	37,510					$	36,098
Stockholders’ Equity
Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued							–						–
Common stock, $.0001 par value; authorized 200,000,000 shares; issued and outstanding 21,990,000 and 21,802,515, as of December 31, 2012 and issued and outstanding 21,330,235 and 21,132,545 as of December 31, 2011, respectively
							2						2
Additional paid-in capital							88,742						87,541
Accumulated other comprehensive loss							–						(136	)
Retained deficit							(48,731	)					(47,242	)
Total Stockholders’ Equity							40,013						40,165
Total Liabilities and Stockholders’ Equity						$	77,523					$	76,263

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS
						Three Months Ended												Twelve Months Ended
						December 31,												December 31,
						(Unaudited)
(in thousands, except share data)						2012						2011						2012						2011
Net revenues:
Rentals						$	14,568					$	11,933					$	53,471					$	46,795
Product sales							1,665						2,109						5,357						7,842
Net revenues							16,233						14,042						58,828						54,637
Cost of revenues:
Cost of revenues – Product, service and supply costs							2,405						2,465						9,165						9,128
Cost of revenues – Pump depreciation and loss on disposal							1,824						3,495						6,752						10,154
Gross profit							12,004						8,082						42,911						35,355
Selling, general and administrative expenses:
Provision for doubtful accounts							2,132						1,066						5,251						4,099
Amortization of intangibles							706						671						2,734						2,662
Asset impairment charges							–						–						–						67,592
Selling and marketing							2,229						2,283						9,864						9,371
General and administrative							5,374						4,759						23,062						17,987
Total selling, general and administrative:							10,441						8,779						40,911						101,711
Operating income (loss)							1,563						(697	)					2,000						(66,356	)
Other income (loss):
Gain on derivatives							–						–						–						83
Interest expense							(1,105	)					(547	)					(3,340	)					(2,193	)
Loss on extinguishment of long term debt							(119	)					–						(671	)					–
Other (expense) income							(7	)					8						(141	)					(111	)
Total other loss							(1,231	)					(539	)					(4,152	)					(2,221	)
Income (loss) before income taxes							332						(1,236	)					(2,152	)					(68,577	)
Income tax (expense) benefit							(111	)					473						663						23,134
Net income (loss)						$	221					$	(763	)				$	(1,489	)				$	(45,443	)
Net income (loss) per share:
Basic						$	0.01					$	(0.04	)				$	(0.07	)				$	(2.16	)
Diluted						$	0.01					$	(0.04	)				$	(0.07	)				$	(2.16	)
Weighted average shares outstanding:
Basic							21,784,115						21,056,634						21,430,012						21,074,093
Diluted							22,019,393						21,056,634						21,430,012						21,074,093

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS
						Year Ended						Year Ended
						December 31,						December 31,
(in thousands)						2012						2011
OPERATING ACTIVITIES
Net loss						$	(1,489	)				$	(45,443	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Gain on derivative liabilities							–						(83	)
Loss on extinguishment of long-term debt							671						–
Provision for doubtful accounts							5,251						4,099
Depreciation							5,668						6,386
Loss on disposal of medical equipment							237						1,731
Gain on sale of medical equipment							(1,964	)					(2,753	)
Amortization of intangible assets							2,734						2,662
Asset impairment charges							–						67,592
Amortization of deferred debt issuance costs							228						238
Stock-based compensation							964						1,185
Deferred income taxes							(906	)					(23,423	)
Changes in Assets – (Increase)/Decrease, exclusive of effects of acquisitions:
Accounts receivable							(6,490	)					(4,419	)
Inventory							(30	)					33
Other current assets							249						(184	)
Other assets							664						657
Changes in Liabilities – Increase/(Decrease), exclusive of effects of acquisitions:
Accounts payable and other liabilities							(335	)					(1,532	)
NET CASH PROVIDED BY OPERATING ACTIVITIES							5,452						6,746
INVESTING ACTIVITIES
Purchases of medical equipment and property							(6,542	)					(8,211	)
Proceeds from sale of medical equipment and property							3,978						4,218
Acquisition of intangible assets							–						(625	)
Other asset acquisitions							6						(509	)
NET CASH USED IN INVESTING ACTIVITIES							(2,558	)					(5,127	)
FINANCING ACTIVITIES
Principal payments on term loans and capital lease obligations							(9,631	)					(5,953	)
Payoff of bank loan and revolver							(25,851	)					–
Cash proceeds from bank loans and revolving credit facility							37,101						2,334
Payments on revolving credit facility							–						(1,750	)
Payments for debt issuance costs							(2,842	)					–
Common stock repurchased to satisfy taxes on stock based compensation							(144	)					(102	)
Treasury shares repurchased							–						(363	)
NET CASH USED IN FINANCING ACTIVITIES							(1,367	)					(5,834	)
Net change in cash and cash equivalents							1,527						(4,215	)
Cash and cash equivalents, beginning of period							799						5,014
Cash and cash equivalents, end of period						$	2,326					$	799

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES GAAP RECONCILIATION (UNAUDITED)
					Three Months Ended										Twelve Months Ended
					December 31,										December 31,
(in thousands)					2012				2011						2012					2011
Net income (loss)					$	221			$	(763	)				$	(1,489	)			$	(45,443	)
Adjustments:
Interest expense						1,105				547						3,340					2,193
Income tax expense (benefit)						111				(473	)					(663	)				(23,134	)
Depreciation						1,325				1,496						5,668					6,386
Amortization						706				670						2,734					2,662
EBITDA						3,468				1,477						9,590					(57,336	)
Asset impairment charges						–				–						–					67,592
EBITDA – excluding impairment charges						3,468				1,477						9,590					10,256
Concerned Stockholder Group						17				–						2,220					–
Early Extinguishment of Debt						119				–						671					–
Strategic Alternatives						179				–						645					–
EBITDA – Adjusted					$	3,783			$	1,477					$	13,126				$	10,256